LACTOLOGY FOUNDATION

Diphemanil (ATC A03AB15) is a quaternary ammonium antimuscarinic used mainly for functional gastrointestinal disorders and hypersecretory conditions, with a typical anticholinergic toxicity profile and very scarce, largely theoretical information regarding its safety in breastfeeding women. In lactation, its use should generally be limited to short courses only when clearly needed, with preference for better‑characterized alternatives and careful monitoring of both mother and breastfed infant.wikipedia+5

Classification and clinical uses

Diphemanil (usually as diphemanil methylsulfate) belongs to ATC group A03AB “synthetic anticholinergics, quaternary ammonium compounds,” with the specific code A03AB15. It is an antimuscarinic (parasympatholytic) agent used for peptic ulcer disease, gastric hyperacidity, gastrointestinal hypermotility/functional bowel disorders, and sometimes for conditions such as hyperhidrosis or Frey’s syndrome.medpedia.framar+5

On Bulgarian Medpedia/Framar it is listed succinctly as an antimuscarinic medicament, with general information on indications (grouped with antiparkinsonian antimuscarinics), contraindications such as hypersensitivity, and the need for physician‑determined dosing and prescription‑only access. Internationally, its clinical use has declined and is now limited or historical in many countries, similar to several other older A03AB anticholinergics.drugbank+2

Mechanism of action and pharmacodynamics

Diphemanil is a quaternary ammonium antimuscarinic that competitively antagonizes muscarinic acetylcholine receptors, particularly in peripheral tissues. By blocking muscarinic receptors in the gastrointestinal tract, it decreases smooth‑muscle tone and motility and reduces secretion, producing an antispasmodic and antisecretory effect.glpbio+2

Its quaternary structure confers poor lipid solubility and limits penetration across the blood–brain barrier compared with tertiary amines, so central nervous system effects are generally less pronounced but not entirely absent at higher doses. Like other anticholinergics, it also reduces secretions in salivary, bronchial and sweat glands, an effect exploited in hyperhidrosis and related conditions but contributing to systemic adverse effects.drugs.ncats+4

Pharmacokinetics and systemic exposure

As a quaternary ammonium compound, diphemanil exhibits limited oral absorption and restricted distribution into highly lipophilic compartments compared with tertiary antimuscarinics. Systemic exposure can nevertheless be clinically significant, especially with repeated or high dosing, and elimination is primarily via renal excretion, with details varying between sources and products.drugcentral+4

The low lipid solubility suggests reduced transfer across the blood–brain barrier and, theoretically, lower passive diffusion into breast milk compared with more lipophilic anticholinergics. However, in the absence of direct milk‑level data, standard lactation principles still recommend using the lowest effective dose for the shortest necessary duration to minimize infant exposure.iris.who+4

Adverse effects and toxicity

Diphemanil shares the class‑typical anticholinergic adverse‑effect spectrum, including dry mouth, constipation, decreased sweating, blurred vision, tachycardia and urinary retention. Dose‑related anticholinergic effects can also precipitate hyperthermia (due to anhidrosis), confusion or agitation, especially in susceptible or elderly patients.consultant360+4

In overdose or in patients with high sensitivity, a full anticholinergic toxidrome may develop: flushed dry skin, hyperthermia, mydriasis with photophobia, tachycardia, ileus, urinary retention, delirium and, in severe cases, cardiac arrhythmias or circulatory collapse. Management of significant toxicity follows general anticholinergic‑poisoning principles: withdrawal of the offending agent, supportive care (IV fluids, cooling, monitoring), treatment of agitation/delirium and, in selected severe cases, cautious use of physostigmine in an experienced setting.rch+2

Contraindications and precautions

Usual antimuscarinic contraindications apply, including known hypersensitivity, narrow‑angle glaucoma, urinary retention, significant prostatic hypertrophy, mechanical gastrointestinal obstruction, paralytic ileus and severe ulcerative colitis or toxic megacolon. Caution is advised in cardiovascular disease (tachyarrhythmias, heart failure), hyperthyroidism, autonomic neuropathy and conditions predisposing to gastric reflux, because anticholinergics can worsen tachycardia, impair sweating and affect gastric emptying.goodrx+3

Older adults, patients with cognitive impairment and those on multiple anticholinergic medications are at increased risk of confusion, falls and cumulative anticholinergic burden, which has been associated with long‑term cognitive decline in observational data. For topical or localized formulations (e.g. for hyperhidrosis or Frey’s syndrome), systemic absorption is lower but still possible, especially when applied over large areas, under occlusion or on compromised skin.pubmed.ncbi.nlm.nih+3

Pregnancy and general reproductive safety

Data on diphemanil use in pregnancy are limited, and it is not considered a first‑line agent for gastrointestinal or secretory problems in pregnant women. In the absence of robust human safety data, most guidelines favor better‑studied alternatives with established pregnancy safety profiles, using diphemanil only when the expected maternal benefit clearly outweighs potential fetal risks.medsafe+4

General principles for anticholinergic use in pregnancy include minimizing dose and duration, avoiding polypharmacy with other anticholinergics, and careful monitoring for maternal tachycardia, decreased gut motility and urinary retention. If treatment is needed in late pregnancy, clinicians should consider potential neonatal adaptation issues, such as transient ileus or urinary retention, though evidence specific to diphemanil is lacking.consultant360+2

Breastfeeding: pharmacological and clinical considerations

In contrast to some obstetric and anesthetic drugs, diphemanil has virtually no direct published data on excretion into human breast milk or measured infant exposure. Its quaternary structure and limited lipid solubility would suggest low passive diffusion into breast milk, but meaningful systemic maternal exposure means that some transfer cannot be excluded.wikipedia+4

Authoritative breastfeeding references (e.g. WHO “Breastfeeding and maternal medication” and national lactation guidance) generally classify short‑term use of most antimuscarinic agents as compatible with breastfeeding when clinically justified, provided repeated and high‑dose exposure is avoided because anticholinergics may inhibit oxytocin release and potentially reduce milk ejection or overall milk supply. In line with these general principles, diphemanil during lactation should be considered a drug with theoretical risk: occasional short courses may be acceptable if needed, but routine, high‑dose or long‑term treatment in breastfeeding women is not preferred.nhs+2

Potential effects on milk production and infant

Anticholinergic drugs can interfere with the neuroendocrine reflexes involved in lactation, particularly oxytocin‑mediated let‑down, and in some cases may contribute to reduced milk production or more difficult milk ejection. Although this effect has not been specifically quantified for diphemanil, similar warnings are given in lactation guidance for other anticholinergics, which supports a cautious, time‑limited approach.iris.who+2

For the breastfed infant, theoretical risks include anticholinergic symptoms such as poor feeding, constipation, decreased sweating, urinary retention, tachycardia and, at higher exposures, sedation, irritability or temperature dysregulation. Premature neonates, newborns and infants with renal impairment or other comorbidities are more vulnerable to such effects and may require stricter avoidance or enhanced monitoring when the mother receives anticholinergic therapy.mayoclinic+4

Practical breastfeeding recommendations

When diphemanil is considered in a breastfeeding woman, the indication should be reviewed carefully, and non‑pharmacological measures or alternative agents with better lactation data should be considered first, especially for chronic gastrointestinal complaints. If diphemanil is used, it is advisable to prescribe the lowest effective dose for the shortest possible duration, schedule doses immediately after a feed when feasible, and avoid using it in combination with multiple other anticholinergic drugs.medsafe+2

During maternal treatment, the infant should be monitored for feeding difficulties, inadequate weight gain, constipation, unusual dryness (mouth, skin, decreased sweating), urinary retention, or abnormal behavior (excessive sleepiness, agitation, temperature instability), and breastfeeding women should be asked proactively about perceived changes in milk flow or supply. If significant anticholinergic effects are suspected in the infant or a notable decline in lactation occurs, the drug should be re‑evaluated and, if possible, discontinued or replaced, with appropriate pediatric assessment.mayoclinic+4

Lactation risk stratification and duration of exposure

For occasional single doses or very short courses (e.g. a few days) in a healthy mother of a term infant, diphemanil can be considered of low to moderate risk, provided clinical monitoring is in place and dosing remains modest. For prolonged or high‑dose therapy, especially in the early postpartum period when lactation is being established, the risk of impacting milk production and cumulative infant exposure increases, and alternative therapies are preferred.nhs+3

In mothers of premature infants, neonates less than a few weeks old, or medically fragile babies, both anticholinergic toxicity and altered pharmacokinetics in the child argue for avoiding diphemanil or using it only in exceptional situations with close specialist supervision. Where available, consultation of up‑to‑date lactation databases and local pharmacovigilance resources is recommended to refine individual risk assessment and keep pace with any emerging case reports.iris.who+3